All Oncology News

Geoffrey Oxnard, MD, discusses testing error underlying liquid biopsy discordance, steps clinicians can take to optimize liquid biopsy, and where he sees this evolving in the treatment landscape for patients with cancer.

Ana Oaknin, MD, provides insight into the implications of the GARNET trial and the promise of dostarlimab in endometrial cancer.

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

Sai-Hong I. Ou, MD, highlights the conveniences of liquid biopsies relative to tissue biopsies, as well as current drawbacks to their use in detecting targetable alterations in lung cancer.

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

The University of Texas MD Anderson Cancer Center named David Jaffray, PhD, as its first-ever chief technology and digital officer.

Lyudmila A. Bazhenova, MD, discusses the phase III PACIFIC trial and clinical scenarios that warrant further investigation in the field of stage III non–small cell lung cancer.

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Bing Xia, MD, discusses the latest immunotherapy developments in nonsquamous non–small cell lung cancer, as well as sequencing strategies for patients with ALK-positive disease.

Nicolas Girad, MD, discusses the importance of evaluating durvalumab in a real-world setting, other questions that remain unanswered in this area, and the role of immunotherapy in patients with non–small cell lung cancer.

Single-agent pembrolizumab (Keytruda) did not meet a prespecified endpoint of superior overall survival compared with chemotherapy as a second- or third-line treatment for patients with metastatic triple-negative breast cancer, missing the primary endpoint of the phase III KEYNOTE-119 trial.

Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.

Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation (OXPHOS) and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib (Imbruvica) in mantle cell lymphoma.

Danielle M. Brander, MD, discusses the investigational combination treatments that are bringing patients with chronic lymphocytic leukemia one step closer to well-tolerated, time-limited therapy.

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.

Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, sheds light on initial treatment approaches for patients with EGFR-mutant NSCLC and adapted therapeutic strategies at the time of progression.

Ivosidenib demonstrated a statistically significant improvement in progression-free survival by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma.

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

The European Commission has granted an approval to lenalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant, as well as pomalidomide in combination with bortezomib and dexamethasone for the treatment of adult patients with myeloma who have received ≥1 prior treatment regimen that included lenalidomide.

The FDA has approved the combination of venetoclax and obinutuzumab for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.

The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

The FDA’s Oncologic Drugs Advisory Committee voted 8-3 against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Richard Bold, MD, chief of the Division of Surgical Oncology, has been named Physician-in-Chief of the UC Davis Comprehensive Cancer Center.

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor.